Electra Therapeutics Inc.
Clinical trials sponsored by Electra Therapeutics Inc., explained in plain language.
-
New hope for rare blood cancers: experimental drug ELA026 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called ELA026 in adults with T/NK cell blood cancers that have come back or not responded to prior treatments. The main goals are to check the drug's safety and find the right dose. About 84 participants will be enrolled across mu…
Phase: PHASE1 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug targets deadly immune overreaction in rare disease
Disease control Recruiting nowThis study tests a new drug, ELA026, for people with secondary hemophagocytic lymphohistiocytosis (sHLH), a rare and life-threatening condition where the immune system becomes dangerously overactive. The drug aims to calm this overreaction by removing certain immune cells. The tr…
Phase: PHASE2, PHASE3 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC